<?xml version="1.0" encoding="UTF-8"?>
<p>Tang et al. (
 <xref rid="B176" ref-type="bibr">2020</xref>) confirmed that anticoagulant therapy by heparin (an anticoagulant) specially with low molecular weight heparin improved the prognosis in severely ill patients with nCOVID-19. Furthermore, 28-day mortality of heparin receivers was found to be lower as compared to the non-users among individuals with sepsis-stimulated coagulopathy scores 4 or D-dimer &gt; 6-times the upper limit of normal (Tang et al., 
 <xref rid="B176" ref-type="bibr">2020</xref>).
</p>
